John M. Burke, MD

John Burke, MD
Conference Coverage
First-Line Subcutaneous Mosunetuzumab Shows Encouraging Efficacy, Manageable Safety for Patients With Low Tumor Burden Follicular Lymphoma
12/13/2024
According to updated results presented by John Burke, MD, at the 66th ASH Annual Meeting, frontline subcutaneous treatment with fixed-duration mosunetuzumab among patients with low-tumor burden FL demonstrated efficacy and safety.
According to updated results presented by John Burke, MD, at the 66th ASH Annual Meeting, frontline subcutaneous treatment with fixed-duration mosunetuzumab among patients with low-tumor burden FL demonstrated efficacy and safety.
According to updated results...
12/13/2024
Oncology
John Burke, MD
Interview
Challenges in Initiating Venetoclax-Based Treatment for Patients With CLL
12/11/2024
John M. Burke, MD, Rocky Mountain Cancer Centers, provides an overview of his study that examined the barriers providers face in initiating venetoclax-based treatment for patients with chronic lymphocytic leukemia (CLL).
John M. Burke, MD, Rocky Mountain Cancer Centers, provides an overview of his study that examined the barriers providers face in initiating venetoclax-based treatment for patients with chronic lymphocytic leukemia (CLL).
John M. Burke, MD, Rocky...
12/11/2024
Journal of Clinical Pathways
Research Reports
Barriers to Lymphoma Clinical Practice Guideline Adherence: A Pilot Mixed-Methods Research Study
04/16/2019
Abstract: Little is published about adherence barriers to lymphoma clinical practice guidelines (CPGs). This article examines the most frequent barriers to adherence to lymphoma CPGs. An explanatory sequential...
Abstract: Little is published about adherence barriers to lymphoma clinical practice guidelines (CPGs). This article examines the most frequent barriers to adherence to lymphoma CPGs. An explanatory sequential...
...
04/16/2019
Journal of Clinical Pathways
Treatment Pathways for First-Line Metastatic Non-Small Cell Lung Cancer: Cost and Survival
Research Reports
Treatment Pathways for First-Line Metastatic Non-Small Cell Lung Cancer: Cost and Survival
10/21/2020
Abstract: Value Pathways powered by NCCN™ provides oncologists with a list of clinically proven treatment options that support the delivery of high-quality, cost-effective cancer care. We evaluated the economic and...
Abstract: Value Pathways powered by NCCN™ provides oncologists with a list of clinically proven treatment options that support the delivery of high-quality, cost-effective cancer care. We evaluated the economic and...
...
10/21/2020
Journal of Clinical Pathways
John Burke, MD, video thumbnail.
Videos
Chronic Lymphocytic Leukemia Pathways in Practice at Rocky Mountain Cancer Centers
02/05/2024
John Burke, MD, discusses the current treatment landscape for chronic lymphocytic leukemia and how his center ensures a comprehensive approach to patient care.
John Burke, MD, discusses the current treatment landscape for chronic lymphocytic leukemia and how his center ensures a comprehensive approach to patient care.
John Burke, MD, discusses the...
02/05/2024
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
LLM Winter Symposium
February 7 ⁠–⁠ February 9
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
GD Solid Tumors
March 22 ⁠–⁠ March 23
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 4
WoundCon
May 1 ⁠–⁠ May 3
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use